Benefits
Anti-inflammatory and pain relief
Bromelain reduces prostaglandin production, bradykinin activity, and inflammatory cytokines. Multiple RCTs show comparable efficacy to NSAIDs for joint pain, sinusitis, and surgical tissue swelling.
Digestive enzyme support
Bromelain breaks down dietary proteins in the GI tract, improving digestion and reducing protein-related bloating and discomfort. Clinically useful in pancreatic enzyme insufficiency.
Post-exercise recovery
Studies show bromelain reduces DOMS (delayed onset muscle soreness) markers, swelling, and recovery time after intense exercise, accelerating return to training.
Sinus and respiratory support
European clinical trials show bromelain significantly reduces nasal inflammation, congestion, and mucus production in sinusitis with effects comparable to pharmaceutical decongestants.
Mechanism of action
Prostaglandin synthesis inhibition
Bromelain inhibits cyclooxygenase (COX) enzymes and thromboxane production, reducing prostaglandin E2 and other pro-inflammatory eicosanoids — similar mechanism to NSAIDs but with fewer GI side effects.
Fibrinolytic activity
Bromelain cleaves fibrinogen and degrades fibrin clots, reducing blood viscosity and platelet aggregation. This fibrinolytic effect supports circulation and reduces edema formation after injury.
Immune cell modulation
Bromelain alters CD44 surface marker expression on T-cells, shifts immune responses from Th2 to Th1 type, and enhances NK cell cytotoxicity and immune surveillance.
Clinical trials
Randomized controlled trial comparing bromelain (90 mg three times daily, total 270 mg/day) vs diclofenac (100 mg/day, slow-release) in 90 patients with painful osteoarthritis of the knee for 6 weeks. Outcomes: pain, stiffness, function (Lequesne index), tolerability. (Akhtar et al. 2004, Clin Rheumatol)
90 patients with knee osteoarthritis. 6-week intervention.
Bromelain and diclofenac produced similar reductions in pain, stiffness, and functional impairment. Both groups improved significantly. Bromelain group experienced significantly fewer GI side effects. Note: bromelain dose used was relatively low (270 mg/day); higher doses (1000-2000 mg/day) are used in some clinical applications. Single trial — replication needed.
Systematic review of clinical studies examining bromelain for acute or chronic rhinosinusitis. Outcomes: nasal inflammation, congestion, duration of illness, recovery time. (Guo et al. 2006, In Vivo)
Pooled across multiple sinusitis trials.
Bromelain reduced nasal inflammation, swelling, and congestion scores vs placebo or standard care alone. Duration of illness was shortened. Mechanism likely involves proteolytic activity reducing fibrin deposits and pro-inflammatory mediators. Note: bromelain is used as adjunctive therapy alongside standard sinusitis treatment in some European clinical practices.